Sign up to save your podcasts
Or
Share Zombie Shark
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Zombie Shark
Lauren and JJ investigate a case of collapse in a middle-aged dog.
This episode includes a detailed discussion of hemoabdomen and splenic hemangiosarcoma in the dog.
References
Primary sources of information for this episode:
(1) Rothrock, K., Smrkovski, K., & Rosenthal, R. C. (2021). Hemangiosarcoma, splenic (canine). VINcyclopedia. Last updated 5/8/2021. Last accessed 5/26/2022. www.vin.com
(2) Pope, K. (2018). Evidince-informed integrative oncology: Canine splenic hemangiosarcoma. Southwest Veterinary Symposium Proceedings, 2018.
Information about rates of metastasis, splenectomy as a palliative procedure, and poor overall survival rates:
(1) Pope, K. (2018). Evidince-informed integrative oncology: Canine splenic hemangiosarcoma. Southwest Veterinary Symposium Proceedings, 2018.
(2) Clifford, C. A. & Liptak, J. M. (2017). Splenic tumors. Atlantic Coast Veterinary Conference Proceedings, 2017.
(3) Batschinski, K., Nobre, A., Vargas-Mendez, E., Tedardi, M. V., Cirillo, J., Castari, G., Ubukata, R., & Dagli, M. L. (2018). Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014). The Canadian Veterinary Journal, 59(9), 967-972.
(4) Wendelburg, K. M., Price, L. L., Burgess, K. E., Lyons, J. A., Lew, F. H., & Berg, J. (2015). Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). Journal of the American Veterinary Medical Association, 247(4), 393-403.
Information about median survival times:
(1) Thamm, D., Withrow, S. W. (2013). Miscellaneous tumors: Hemangiosarcoma. Withrow & MacEwen’s Small Animal Clinical Oncology,St. Louis, MO. Saunders/Elsevier, 679-88.
(2) Aronsohn, M. G., Dubiel, B., Roberts, B., & Powers, B. E. (2009). Prognosis for acute nontraumatic hemoperitoneum in the dog: a retrospective analysis of 60 cases (2003-2006). Journal of the American Animal Hospital Association, 45(2), 72–77.
(3) Collard, F., Nadeau, M. E., & Carmel, E. N. (2010). Laparoscopic splenectomy for treatment of splenic hemangiosarcoma in a dog. Veterinary surgery : VS, 39(7), 870–872.
(4) Marconato, L., Chalfon, C., Finotello, R., Polton, G., Vasconi, M. E., Annoni, M., Stefanello, D., Mesto, P., Capitani, O., Agnoli, C., Amati, M., & Sabattini, S. (2019). Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology. Veterinary and comparative oncology, 17(4), 537–544.
A selection of information about chemotherapy and adjunctive treatments for hemangiosarcoma (outside of the scope of this episode, for further reading):
(1) Wendelburg, K. M., Price, L. L., Burgess, K. E., Lyons, J. A., Lew, F. H., & Berg, J. (2015). Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). Journal of the American Veterinary Medical Association, 247(4), 393-403.
(2) Alexander, C. K., Cronin, K. L., Silver, M., Gardner, H. L., & London, C. (2019). The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma. Journal of Small Animal Practice, 66(1), 32-37.
(3) Matsuyama, A., Poirier, V. J., Mantovani, F., Foster, R. A., & Mutsaers, A. J. (2017). Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma. Journal of the American Animal Hospital Association, 53(6), 304-312.
(4) Teske, E., Rutteman, G. R., Kirpenstein, J., & Hirschberger, J. (2011). A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma. Veterinary and Comparative Oncology, 9(4), 283-89.
(5) Kahn, S. A., Mullin, C. M., de Lormier, L. P., Burgess, K. E., Risbon, R. E., Fred, R. M., Drobatz, K., & Clifford, C. A. (2013) Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: A pilot study. The Canadian Veterinary Journal, 54(3) 237-42.
(6) Kim, S. E., Liptak, L. M., Gall, T. T., Montelth, G. J., & Woods, P. (2007). Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004). Journal of the American Veterinary Medical Association, 231(10), 1550-57.
(7) Alvarez, F. J., Hosoya, K., Lara-Garcia, A., Kisseberth, W., & Couto, G. (2013). VAC protocol for treatment of dogs with stage III hemangiosarcoma. Journal of the American Animal Hospital Association, 49(6), 370-77.
(8) Marconato, L., Chalfon, C., Finotello, R., Polton, G., Vasconi, M. E., Annoni, M., Stefanello, D., Mesto, P., Capitani, O., Agnoli, C., Amati, M., & Sabattini, S. (2019). Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology. Veterinary and Comparative Oncology, 17(4), 537-44.
(9) Gardner, H. L., London, C. A., Portela, R. A., Nguyen, S., Rosenberg, M. P., Klein, M. K., Clifford, C., Thamm, D. H., Vail, D. M., Bergman, P., Crawford-Jakubiak, M., Henry, C., Locke, J., & Garrett, L. D. (2015). Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BioMed Central Veterinary Research, 11(0), 131.
(10) Lana, S., U'ren, L., Plaza, S., Elmslie, R., Gustafson, D., Morley, P., & Dow, S. (2007). Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of Veterinary Internal Medicine, 21(4), 764-69.
(11) Vail, D. M., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R., Helfand, S. C., Kisseberth, W. C., London, C. A., Obradovich, J. E., Madewell, B. R., & Rodriguez, C. O. (1995). Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1(10), 1165-70.
(12) Grammel, T. (2016). A pilot, uncontrolled study of postsurgical treatment with autologous dendritic cell-based immunologic therapy in 10 dogs with splenic hemangiosarcoma. Veterinary Cancer Society World Congress Proceedings, 2016.
View all episodes
By IntroVETS Podcast
4.9
2828 ratings
Lauren and JJ investigate a case of collapse in a middle-aged dog.
This episode includes a detailed discussion of hemoabdomen and splenic hemangiosarcoma in the dog.
References
Primary sources of information for this episode:
(1) Rothrock, K., Smrkovski, K., & Rosenthal, R. C. (2021). Hemangiosarcoma, splenic (canine). VINcyclopedia. Last updated 5/8/2021. Last accessed 5/26/2022. www.vin.com
(2) Pope, K. (2018). Evidince-informed integrative oncology: Canine splenic hemangiosarcoma. Southwest Veterinary Symposium Proceedings, 2018.
Information about rates of metastasis, splenectomy as a palliative procedure, and poor overall survival rates:
(1) Pope, K. (2018). Evidince-informed integrative oncology: Canine splenic hemangiosarcoma. Southwest Veterinary Symposium Proceedings, 2018.
(2) Clifford, C. A. & Liptak, J. M. (2017). Splenic tumors. Atlantic Coast Veterinary Conference Proceedings, 2017.
(3) Batschinski, K., Nobre, A., Vargas-Mendez, E., Tedardi, M. V., Cirillo, J., Castari, G., Ubukata, R., & Dagli, M. L. (2018). Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014). The Canadian Veterinary Journal, 59(9), 967-972.
(4) Wendelburg, K. M., Price, L. L., Burgess, K. E., Lyons, J. A., Lew, F. H., & Berg, J. (2015). Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). Journal of the American Veterinary Medical Association, 247(4), 393-403.
Information about median survival times:
(1) Thamm, D., Withrow, S. W. (2013). Miscellaneous tumors: Hemangiosarcoma. Withrow & MacEwen’s Small Animal Clinical Oncology,St. Louis, MO. Saunders/Elsevier, 679-88.
(2) Aronsohn, M. G., Dubiel, B., Roberts, B., & Powers, B. E. (2009). Prognosis for acute nontraumatic hemoperitoneum in the dog: a retrospective analysis of 60 cases (2003-2006). Journal of the American Animal Hospital Association, 45(2), 72–77.
(3) Collard, F., Nadeau, M. E., & Carmel, E. N. (2010). Laparoscopic splenectomy for treatment of splenic hemangiosarcoma in a dog. Veterinary surgery : VS, 39(7), 870–872.
(4) Marconato, L., Chalfon, C., Finotello, R., Polton, G., Vasconi, M. E., Annoni, M., Stefanello, D., Mesto, P., Capitani, O., Agnoli, C., Amati, M., & Sabattini, S. (2019). Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology. Veterinary and comparative oncology, 17(4), 537–544.
A selection of information about chemotherapy and adjunctive treatments for hemangiosarcoma (outside of the scope of this episode, for further reading):
(1) Wendelburg, K. M., Price, L. L., Burgess, K. E., Lyons, J. A., Lew, F. H., & Berg, J. (2015). Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). Journal of the American Veterinary Medical Association, 247(4), 393-403.
(2) Alexander, C. K., Cronin, K. L., Silver, M., Gardner, H. L., & London, C. (2019). The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma. Journal of Small Animal Practice, 66(1), 32-37.
(3) Matsuyama, A., Poirier, V. J., Mantovani, F., Foster, R. A., & Mutsaers, A. J. (2017). Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma. Journal of the American Animal Hospital Association, 53(6), 304-312.
(4) Teske, E., Rutteman, G. R., Kirpenstein, J., & Hirschberger, J. (2011). A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma. Veterinary and Comparative Oncology, 9(4), 283-89.
(5) Kahn, S. A., Mullin, C. M., de Lormier, L. P., Burgess, K. E., Risbon, R. E., Fred, R. M., Drobatz, K., & Clifford, C. A. (2013) Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: A pilot study. The Canadian Veterinary Journal, 54(3) 237-42.
(6) Kim, S. E., Liptak, L. M., Gall, T. T., Montelth, G. J., & Woods, P. (2007). Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004). Journal of the American Veterinary Medical Association, 231(10), 1550-57.
(7) Alvarez, F. J., Hosoya, K., Lara-Garcia, A., Kisseberth, W., & Couto, G. (2013). VAC protocol for treatment of dogs with stage III hemangiosarcoma. Journal of the American Animal Hospital Association, 49(6), 370-77.
(8) Marconato, L., Chalfon, C., Finotello, R., Polton, G., Vasconi, M. E., Annoni, M., Stefanello, D., Mesto, P., Capitani, O., Agnoli, C., Amati, M., & Sabattini, S. (2019). Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology. Veterinary and Comparative Oncology, 17(4), 537-44.
(9) Gardner, H. L., London, C. A., Portela, R. A., Nguyen, S., Rosenberg, M. P., Klein, M. K., Clifford, C., Thamm, D. H., Vail, D. M., Bergman, P., Crawford-Jakubiak, M., Henry, C., Locke, J., & Garrett, L. D. (2015). Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BioMed Central Veterinary Research, 11(0), 131.
(10) Lana, S., U'ren, L., Plaza, S., Elmslie, R., Gustafson, D., Morley, P., & Dow, S. (2007). Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of Veterinary Internal Medicine, 21(4), 764-69.
(11) Vail, D. M., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R., Helfand, S. C., Kisseberth, W. C., London, C. A., Obradovich, J. E., Madewell, B. R., & Rodriguez, C. O. (1995). Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 1(10), 1165-70.
(12) Grammel, T. (2016). A pilot, uncontrolled study of postsurgical treatment with autologous dendritic cell-based immunologic therapy in 10 dogs with splenic hemangiosarcoma. Veterinary Cancer Society World Congress Proceedings, 2016.